Safety and Efficacy of Cerebrolysin for Neurorecovery After Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of 14 Randomized Controlled Trials
Review of earlier studies · 2025
- What was studied
- 2025 meta-analysis reporting 14 randomized trials
- Main finding
- The review reports a neurological-scale benefit, but functional independence and mortality were not significantly improved.
Study data at a glance
- Participants or experimental model
- 2025 meta-analysis reporting 14 randomized trials
- Reported results
- The review reports a neurological-scale benefit, but functional independence and mortality were not significantly improved.
Study limitations and source details
Study limitations
- Table 8 calls hemorrhagic transformation statistically significant, contrary to the abstract’s wording; the discrepancy remains in the publication.
- Tables 2, 5 and 6 list both CARS-1 and the pooled CARS report. CARS denominators also differ between tables (448 versus 240). Cohort independence and extraction need reconciliation.
- Safety totals differ between the headline sample and Table 8. Numerical pooled effects are withheld rather than treated as verified estimates.
Source details
Full PMC article: study-characteristic and outcome tables 1–8 checked. Primary trial datasets and forest-plot inputs have not been independently reconstructed.
Full-text reporting checks; reconstruction pending
Sources checked
Citation
Patel PN, Mangal D, Patel K. Safety and Efficacy of Cerebrolysin for Neurorecovery After Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of 14 Randomized Controlled Trials Cureus · PMID 41018475
Study source ↗ · DOI 10.7759/cureus.91054 · Bibliography entry · Link to this summary